WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018052615) APOM-FC FUSION PROTEINS, COMPLEXES THEREOF WITH SPHINGOSINE L-PHOSPHATE (SIP), AND METHODS FOR TREATING VASCULAR AND NON-VASCULAR DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/052615    International Application No.:    PCT/US2017/046916
Publication Date: 22.03.2018 International Filing Date: 15.08.2017
IPC:
A61K 38/00 (2006.01), C07K 1/00 (2006.01), C12P 21/08 (2006.01)
Applicants: CORNELL UNIVERSITY [US/US]; Center for Technology Licensing at Cornell University (CTL) 395 Pine Tree Road Suite 310 Ithaca, New York 14850 (US)
Inventors: HLA, Timothy T.; (US).
SWENDEMAN, Steven L.; (US).
DILORENZO, Annarita; (US).
SANCHEZ, Theresa; (US)
Agent: GROLZ, Edward W.; (US)
Priority Data:
62/375,088 15.08.2016 US
Title (EN) APOM-FC FUSION PROTEINS, COMPLEXES THEREOF WITH SPHINGOSINE L-PHOSPHATE (SIP), AND METHODS FOR TREATING VASCULAR AND NON-VASCULAR DISEASES
(FR) PROTÉINES DE FUSION APOM-FC, LEURS COMPLEXES AVEC LA SPHINGOSINE 1-PHOSPHATE (S1P), ET MÉTHODES DE TRAITEMENT DE MALADIES VASCULAIRES ET NON VASCULAIRES
Abstract: front page image
(EN)The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.
(FR)La présente invention concerne une protéine chaperon de phospholipide ou lysophospholipide spécifiquement modifiée (par exemple, la sphingosine 1-phosphate (S1P)) dérivée d'une protéine de fusion d'apolipoprotéine M (ApoM)-Fc ayant une demi-vie étendue in vivo. La protéine hybride ApoM-Fc selon l'invention fournit un moyen sûr, efficace et efficient d'administration de la S1P à des cellules endothéliales et à tous les tissus du corps.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)